Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 18/20 | 0.58 |
| ▸ | NR1H2 | P55055 | 16/20 | 0.58 |
| ▸ | NR1H3 | Q13133 | 16/20 | 0.58 |
| ▸ | PPARA | Q07869 | 16/20 | 0.58 |
| ▸ | PPARG | P37231 | 13/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5973747 | 0.85 | PPARD (0.66) | PPARDNR1H2NR1H3PPARAPPARG | |
| SCHEMBL5973350 | 0.83 | PPARD (0.53) | PPARDNR1H2NR1H3PPARAPPARG | |
| SCHEMBL5973183 | 0.83 | PPARD (0.53) | PPARDNR1H2NR1H3PPARAPPARG | |
| SCHEMBL5972939 | 0.82 | PPARD (0.52) | PPARDNR1H2NR1H3PPARAPPARG | |
| SCHEMBL6925941 | 0.82 | PPARD (0.54) | PPARDNR1H2NR1H3PPARAPPARG | |
| SCHEMBL7038876 | 0.81 | PPARD (0.60) | PPARDNR1H2NR1H3PPARAPPARG | |
| SCHEMBL7042207 | 0.81 | PPARD (0.60) | PPARDNR1H2NR1H3PPARAPPARG | |
| SCHEMBL6928324 | 0.81 | PPARD (0.52) | PPARDNR1H2NR1H3PPARAPPARG | |
| SCHEMBL7473597 | 0.80 | PPARD (0.73) | PPARDNR1H2NR1H3PPARAPPARG | |
| SCHEMBL7044588 | 0.79 | PPARG (0.73) | PPARDNR1H2NR1H3PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0948327-B1 | ANTIDIABETIC AGENTS | MERCK & CO INC (US) | 2006-03-08 | — | — | EP | claimed |
| EP-0948327-A4 | ANTIDIABETIC AGENTS | MERCK & CO INC (US) | 2003-04-02 | — | — | EP | claimed |
| US-6160000-A | Antidiabetic agents based on aryl and heteroarylacetic acids | MERCK & CO., INC. (US) | 2000-12-12 | — | — | US | claimed |
| EP-0948327-A1 | ANTIDIABETIC AGENTS | Merck & Co., Inc. (US) | 1999-10-13 | — | — | EP | claimed |
| WO-1998027974-A1 | ANTIDIABETIC AGENTS | MERCK & CO., INC. (US) | 1998-07-02 | — | — | WO | claimed |
| EP-0948327-B1 | ANTIDIABETIC AGENTS | MERCK & CO INC (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-0948327-A4 | ANTIDIABETIC AGENTS | MERCK & CO INC (US) | 2003-04-02 | — | — | EP | disclosed |
| US-6515015-B1 | In combination with one or more known sulfonylureas, biguanides, alpha -glucosidase inhibitors, other insulin secretogogues or insulin | MERCK & CO. INC. | 2003-02-04 | — | — | US | disclosed |
| US-6160000-A | Antidiabetic agents based on aryl and heteroarylacetic acids | MERCK & CO., INC. (US) | 2000-12-12 | — | — | US | disclosed |
| US-6090839-A | REDUCING TRIGLYCERIDE CONCENTRATION | MERCK & CO., INC. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0948327-A1 | ANTIDIABETIC AGENTS | Merck & Co., Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998027974-A1 | ANTIDIABETIC AGENTS | MERCK & CO., INC. (US) | 1998-07-02 | — | — | WO | disclosed |